Astragaloside IV(AS-IV) is a saponin from Astragalus membranaceus. Oral administration of AS-IV (10 and 20 mg/kg) significantly attenuated memory impairment and neuroinflammation[3]. High-dose astragaloside IV has a significant protective effect against D-GalN/LPS-induced (D-galactosamine/lipopolysaccharide-induced ) acute liver injury in mice [4]. High doses of astragaloside IV (10, 20, 40 ng/ml) inhibited NSCLC (non-small cell lung cancer ) cell growth[5]. Astragaloside IV inhibited the viability and invasive potential of MDA-MB-231 breast cancer cells, suppressed the activation of the mitogen activated protein kinase (MAPK) family members ERK1/2 and JNK, and downregulated matrix metalloproteases (MMP)-2 and -9[6].
Astragaloside IV/黄芪甲苷 IV 细胞实验
Cell Line
Concentration
Treated Time
Description
References
Astrocytes
1, 10, 50, 100, 200 µM
10 days
AS-IV inhibited astrocyte replicative senescence, evidenced by decreased senescence-associated β-galactosidase activity and expression of senescence marker p16, increased nuclear level of lamin B1, and reduced pro-inflammatory senescence-associated secretory phenotype.
J Neuroinflammation. 2020 Apr 6;17(1):105.
H9C2 cells
50 µM or 100 µM
24 hours
AS-IV reversed the Dox-induced apoptosis and necrosis of H9C2 cells in a dose-dependent manner.
Chin Med J (Engl). 2022 May 5;135(9):1099-1101.
Caco-2 cells
150 µM
24 hours
To evaluate the inhibitory effect of Astragaloside IV on LPS-induced inflammation in Caco-2 cells, the results showed that Astragaloside IV significantly reversed the inhibition of cell viability by LPS and reduced the production of inflammatory cytokines.
J Transl Med. 2024 Apr 30;22(1):406.
RGC-5 cells
100 mg/L
24 hours
To investigate the protective effect of Astragaloside IV on H2O2-induced oxidative stress injury in RGC-5 cells, the results showed that Astragaloside IV increased cell survival rate, decreased apoptotic cell number, reduced H2O2-induced reactive oxygen species levels, inhibited the decrease of mitochondrial membrane potential, reduced cytochrome c release, inhibited Bax and caspase-3 expression, and increased Bcl-2 expression
To evaluate the protective effects of Astragaloside IV on high glucose-induced podocyte injury, the results showed that Astragaloside IV significantly improved the expression levels of NLRP3, pro-caspase-1 and caspase-1, and inhibited the decrease in cell viability
Int J Mol Med. 2021 Aug;48(2):164.
BMSCs cells
0-80 µM
24, 48, 72 hours
Astragaloside IV significantly enhanced the cell viability of BMSCs at 40 μM, while a further increase in concentration attenuated this effect.
Int J Biol Sci. 2021 Apr 24;17(7):1821-1836.
RAW264.7 cells
10 µM, 40 µM, 80 µM
4 days
Astragaloside IV promoted osteoclast differentiation at low concentrations (10 μM), while osteoclastogenesis was inhibited at higher concentrations with a reduction in the osteoclast area and accumulation of preosteoclasts.
Int J Biol Sci. 2021 Apr 24;17(7):1821-1836.
THP-1 monocytes
80 nM
48 hours
Astragaloside IV significantly inhibited IL-4 and IL-13-induced M2 polarization, as shown by reduced expression of CD206 and M2-associated genes.
J Exp Clin Cancer Res. 2018 Aug 29;37(1):207.
A549 and H1299 lung cancer cells
80 nM
48 hours
Astragaloside IV suppressed M2-CM-induced invasion, migration, and angiogenesis of A549 and H1299 cells.
J Exp Clin Cancer Res. 2018 Aug 29;37(1):207.
Human bone marrow mesenchymal stem cells (BMSCs)
5 µM, 20 µM, 50 µM, 100 µM
To evaluate the effect of AS-IV on BMSCs proliferation, results showed that AS-IV (50 μM) significantly increased BMSCs proliferation.
Cell Prolif. 2023 Nov;56(11):e13485.
Human umbilical vein endothelial cells (HUVECs)
5 µM, 20 µM, 50 µM, 100 µM
To evaluate the effect of AS-IV on HUVECs proliferation, migration, and tube formation ability, results showed that AS-IV (50 μM) significantly promoted HUVECs proliferation, migration, and tube formation ability.
Cell Prolif. 2023 Nov;56(11):e13485.
TM3 cells
100 µM
3 days
AS.IV effectively reduced mutant myocilin associated ER stress
Int J Mol Sci. 2021 Nov 19;22(22):12508.
A549 cells
100 μg/mL
48 hours
To investigate the effect of Astragaloside IV on TGF-β1-induced epithelial-mesenchymal transition (EMT). Results showed that Astragaloside IV significantly reversed TGF-β1-induced EMT, inhibited α-SMA expression, and increased E-cadherin expression.
J Cell Mol Med. 2018 Sep;22(9):4354-4365.
Astragaloside IV/黄芪甲苷 IV 动物实验
Species
Animal Model
Administration
Dosage
Frequency
Description
References
Wistar rats
Dox-induced heart failure model
Intraperitoneal injection
1.0 mg/kg
Once daily for 9 weeks
AS-IV treatment significantly increased the ejection fraction in heart failure rats, reduced cardiomyocyte apoptosis, and reversed the abnormal expression of DRP1 and mitofusin.
Chin Med J (Engl). 2022 May 5;135(9):1099-1101.
Mice
MPTP-induced Parkinson's disease model
Intraperitoneal injection
100 mg/kg
Every 12 hours for 5 weeks
AS-IV protected against the loss of dopamine neurons and behavioral deficits in the mouse model of PD, accompanied by reduced accumulation of senescent astrocytes in substantia nigra compacta.
J Neuroinflammation. 2020 Apr 6;17(1):105.
C57BL/6 mice
DSS-induced colitis model
Oral gavage
100 mg/kg
Once daily for 10 days
To evaluate the therapeutic effect of Astragaloside IV on DSS-induced colitis in mice, the results showed that Astragaloside IV significantly alleviated inflammation, improved intestinal barrier function, and acted by inhibiting the PI3K/AKT signaling pathway.
J Transl Med. 2024 Apr 30;22(1):406.
SD rats
Distraction osteogenesis model
Intragastric administration
20 mg/kg/day
Once daily for 4 weeks
Astragaloside IV accelerated bone regeneration during DO by enhancing osteogenesis and preosteoclast-induced angiogenesis simultaneously, partially through AKT/GSK-3β/β-catenin signaling.
Int J Biol Sci. 2021 Apr 24;17(7):1821-1836.
Sprague-Dawley rats
Glucocorticoid-induced avascular necrosis of the femoral head model
Oral gavage
20 mg/kg/day
Once daily for 6 weeks
To evaluate the protective effect of AS-IV on glucocorticoid-induced avascular necrosis of the femoral head, results showed that AS-IV promoted osteogenesis and angiogenesis via the Akt/Runx2 and Akt/HIF-1α/VEGF pathways, respectively, and suppressed apoptosis and oxidative stress via the Akt/Bad/Bcl-2 and Akt/Nrf2/HO-1 pathways, respectively.
Cell Prolif. 2023 Nov;56(11):e13485.
C57BL/6J mice
Lewis lung cancer model
Intragastric administration
40 mg/kg
Once daily for 21 days
Astragaloside IV significantly inhibited the growth and metastasis of Lewis lung cancer and reduced the percentage of M2 macrophages in tumor tissue.
J Exp Clin Cancer Res. 2018 Aug 29;37(1):207.
Mice
Db/db mice
Intragastric administration
40 mg/kg
Once daily for 12 weeks
To evaluate the protective effects of Astragaloside IV on diabetic nephropathy in db/db mice, the results showed that Astragaloside IV significantly reduced weight gain, hyperglycemia and serum triglyceride levels, improved renal function and podocyte injury, and inhibited NLRP3 inflammasome-mediated inflammation
Int J Mol Med. 2021 Aug;48(2):164.
C57BL/6J mice
DSS-induced colitis model
Oral
50 or 100 mg/kg
Once daily for 10 days
AS-IV attenuated the inflammatory progression of DSS-induced colitis and promoted the phenotypic transition of macrophages from pro-inflammatory to pro-resolving macrophages.
Front Immunol. 2021 Sep 13;12:740565.
Kunming mice
Acute alcohol-induced liver injury model
Oral
50, 150, and 500 mg/kg
Once daily for 7 days
Astragaloside IV ameliorates acute alcohol-induced liver injury by modulating gut microbiota and inhibiting NLRP3/Caspase-1 signaling pathway.
Ann Med. 2023 Dec;55(1):2216942
C57BL/6 mice
Total-body irradiation-induced aging model
Oral gavage
50 mg/kg
Once daily for 2 weeks
To evaluate the improvement effect of CAG on age-related symptoms, results showed that CAG significantly alleviated aging phenotypes (e.g., grayed fur, osteoporosis) and improved behavioral performance in aged mice. Additionally, CAG reduced the expression of senescence markers (e.g., P53, P21, and P16) and decreased the production of SASP factors.
搜索
